USA flag logo/image

An Official Website of the United States Government

EGFR-Targeted Nanoemulsions for Imaging and Therapy of Ovarian Cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95893
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA144591
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
NEMUCORE MEDICAL INNOVATIONS, INC.
33 KIRKLAND CIR WELLESLEY, MA 02481-4812
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: EGFR-Targeted Nanoemulsions for Imaging and Therapy of Ovarian Cancer
Agency: HHS
Contract: 1R43CA144591-01
Award Amount: $302,461.00
 

Abstract:

DESCRIPTION (provided by applicant): Today 70% of patients with advanced ovarian cancer will achieve clinically complete remission with front line treatments of carboplatin and paclitaxel, unfortunately a majority these patients are destined to relapse and eventually die of disease within 12-18 months due to a persistence of chemoresistant cells. Diagnostic techniques for ovarian cancer include normal exam, monitoring CA-125 level and CT-scans all capable of observing gross changes in disease progression bu t are less sensitive at quantitating the number or location of chemoresistant cells. Our overarching strategy addresses the major failures of the front line therapy and diagnostics by using multifunctional nanoemulsions to target, image, and enhance cytoto xicity to simultaneously eradicate chemosensitive and chemoresistant tumor cells. Extending our positive rodent studies combining targeting, imaging and therapeutic in a single vehicle, these proposed studies will focus on engineering multifunctional nanoe mulsions capable of: 1) Targeting EGFR expressing cells which is found on majority of ovarian cancers; 2) imaging disease regression or progression by delivering DPTA-Gd3+, an magnetic resonance imaging (MRI) contrast agent, directly to tumor cells; and 3) enhance the cytotoxicity of carboplatin by targeting but also by co-delivering the pro-apoptotic molecule C6-ceramide, shown to reestablish key apoptosis pathways to overcome chemoresistance. Preclinical studies will be carried out in human ovarian adenoc arcinoma xenograft models in female nu/nu mice to identify key pharmacokinetics parameters, efficacy, and ability to image delivery efficiency and disease progression using MRI. Successful completion of these studies will guide Phase II studies to generate safety, pharmacokinetics, efficacy and scale-up manufacturing data to advance to clinical trials. Phase I outcomes will additionally encourage exploration of enhancing the targeted delivery of other chemotherapeutic drugs or other compounds that had not p reviously been evaluated clinically due to physical properties, bioavailability or toxicities. PUBLIC HEALTH RELEVANCE: An estimated 22,000 new cases in 2008 and approximately 15,000 deaths in the United States, epithelial ovarian cancer is the most lethal of gynecologic cancers, due to its propensity to spread into the upper abdomen and beyond. Frontline lead to clinically complete remission in over 70% of patients, however typically within 12-18 months those patients relapse due to chemoresistant c ells. Diagnostic techniques for ovarian cancer include normal exam, monitoring CA-125 level and CT-scans all capable of observing gross changes in disease progression but are less sensitive at quantitating the number or location of chemoresistant cells. Ou r overarching strategy addresses the major failures of the front line therapy and diagnostics by using multifunctional nanoemulsions to target, image, and enhance cytotoxicity to simultaneously eradicate chemosensitive and chemoresistant tumor cells.

Principal Investigator:

Timothy P. Coleman
6179439983
TCOLEMAN@NEMUCORE.COM

Business Contact:

Small Business Information at Submission:

NEMUCORE MEDICAL INNOVATIONS, INC.
NEMUCORE MEDICAL INNOVATIONS, INC. 33 KIRKLAND CIR WELLESLEY, MA -

EIN/Tax ID: 126190375
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No